Malin Corporation PLC Immunocore Update re tebentafusp (1529G)
November 23 2020 - 3:30AM
UK Regulatory
TIDM0Y71
RNS Number : 1529G
Malin Corporation PLC
23 November 2020
Malin Corporation plc
Immunocore's tebentafusp demonstrates superior overall survival
compared to investigator's choice in a Phase 3 clinical trial of
patients with previously untreated metastatic uveal melanoma
-- First positive Phase 3 clinical trial for any T cell receptor
therapeutic and first for any bispecific in a solid tumour
-- Tebentafusp has the potential to be the first new therapy to
improve OS in patients with metastatic uveal melanoma in 40
years
Dublin-Ireland, 23 November 2020 : Malin Corporation plc.
(Euronext Growth Dublin:MLC) (Malin), a company investing in highly
innovative life sciences companies, is pleased to note that its
investee company, Immunocore Limited, a clinical-stage T cell
receptor biotechnology company, announced today that its Phase 3
IMCgp100-202 clinical trial of tebentafusp (IMCgp100) vs.
investigator choice in metastatic uveal melanoma (mUM) has met the
pre-defined boundaries for statistical significance of the primary
endpoint of Overall Survival (OS) in its first pre-planned interim
analysis conducted by the independent data monitoring committee.
The OS Hazard Ratio (HR) in the intent-to-treat population favoured
tebentafusp, HR=0.51 (95% CI: 0.36, 0.71); p< 0.0001, over
investigator's choice (82% pembrolizumab; 12% ipilimumab; 6%
dacarbazine). Although not yet mature, the Kaplan-Meier estimates
suggest a 1-year OS rate of approximately 73% vs 58%, respectively.
The efficacy data confirm the promising OS observed in the phase 2
study IMCgp100-102 in previously treated mUM which will be
presented next month at the ESMO Immuno-Oncology Virtual Congress
2020. If approved, tebentafusp would be the first new therapy to
improve overall survival in metastatic uveal melanoma in 40 years.
Metastatic uveal melanoma is a disease with poor survival and where
new therapies are urgently needed.
A copy of Immunocore's press release is available to view here:
LINK
Malin currently holds approximately 7% of the issued share
capital of Immunocore.
About Immunocore Limited:
Immunocore is a late-stage biotechnology company pioneering the
development of a novel class of TCR bispecific immunotherapies
called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease
- designed to treat a broad range of diseases, including cancer,
infectious and autoimmune. Leveraging its proprietary, flexible,
off-the-shelf ImmTAX platform, Immunocore is developing a deep
pipeline in multiple therapeutic areas, including five clinical
stage programs in oncology and infectious disease, advanced
pre-clinical programs in autoimmune disease and multiple earlier
pre-clinical programs. Immunocore's most advanced oncology
therapeutic candidate, tebentafusp, has demonstrated monotherapy
activity in a Phase 2 clinical trial in metastatic uveal melanoma,
a cancer that has historically proven to be insensitive to other
immunotherapies, and is currently being studied in an ongoing Phase
3 clinical trial. Collaboration partners include Genentech,
GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, and the Bill
and Melinda Gates Foundation. Immunocore is headquartered at Milton
Park, Oxfordshire, U.K., with offices in Conshohocken, Pennsylvania
and Rockville, Maryland in the United States. For more information,
please visit www.immunocore.com .
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in
highly innovative life sciences companies. Its purpose is to create
shareholder value through the application of long-term capital and
operational and strategic expertise to a diverse range of global
healthcare businesses. Malin has a focus on innovative businesses
underpinned by exceptional science and works with its investee
companies, providing strategic and financial support to enable them
to reach their value potential. Malin is headquartered and
domiciled in Ireland and listed on the Euronext Growth Dublin. For
more information visit www.malinplc.com
For further information please contact:
Malin
Jessica Bergin, Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Davy Corporate Finance (Euronext Growth Adviser & Joint
Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
Liberum (Joint Broker)
Bidhi Bhoma / Euan Brown
Tel: +44 (0) 20 3100 2000
Powerscourt (Irish Media enquiries)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESGIBDBUDDDGGX
(END) Dow Jones Newswires
November 23, 2020 03:30 ET (08:30 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Mar 2024 to Apr 2024
Malin (LSE:0Y71)
Historical Stock Chart
From Apr 2023 to Apr 2024